norm: tasly pharmaceuticalsUSLEI 5493003MW341VK6X8807 · no CIKMax severity: Critical

Canonical registry

Tasly Pharmaceuticals, Inc.

ent_019ef2174c63f2c68c93628f433bf035

Compliance scorecard →🔔 Follow entity

Disclosures

Leak Site · 1 jurisdiction

Incidents

—

no linked incident in sample

Max affected reported

—

no filed count in sample

Leak-site claims

unverified actor claims

Identity resolution

Canonical name: Tasly Pharmaceuticals, Inc.
Normalized: tasly pharmaceuticals— dedupe via name-norm; Microsoft / MSFT collapse to one row
GLEIF LEI: 5493003MW341VK6X8807
SEC EDGAR CIK: None — not an SEC registrant
Domain: taslyus.com

Unverified threat-actor claim — not a regulatory filing

Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.

Disclosure history (1)newest first

GLOBALLeak Siteas victim2023-05-18
Tasly Pharmaceuticals, Inc. (Tasly U.S.) is “Dedicated to a Healthier World.” And our vision is that the world will change the way it takes and understands medicine. Founded in 2006, and following years of research and development, Tasly U.S., based in Rockville, Maryland, is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals. Among our key accomplishments to date: T89 (Dantonic) has become the first herbal medicine-derived compound to complete an FDA Phase III global trial, yielding promising data. Results indicate that T89’s pharmacological functionalities express clinically significant benefits, including improving blood circulation, boosting energy metabolism level, and reducing blood viscosity. Tasly U.S. believes our initial success with T89 will pave the way for the broader use of herbal medication as an effective and safe alternative to synthesized chemical and biological treatments.